MELINTA THERAPEUTICS, INC. /NEW/
MLNT evidence brief
What we can confirm
- BioSniper Score:
- 8.6 / 10
- Lead Asset:
- baxdela (Approved)
What it means
What to watch
Prepared research question
What matters most for MLNT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
baxdela (Approved)
Next Catalyst
—
Tracking 4 pipeline candidates · 2 clinical trials for MELINTA THERAPEUTICS, INC. /NEW/.
Run MELINTA THERAPEUTICS, INC. /NEW/ through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MELINTA THERAPEUTICS, INC. /NEW/ facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is MELINTA THERAPEUTICS, INC. /NEW/'s lead drug candidate?
MELINTA THERAPEUTICS, INC. /NEW/'s most advanced tracked candidate is baxdela (Approved) for acute bacterial skin or skin structure infections (ABSSSI) and community acquired bacterial pneumonia (CABP).
Who is the CEO of MELINTA THERAPEUTICS, INC. /NEW/?
Dova Pharmaceuticals Inc is the chief executive officer of MELINTA THERAPEUTICS, INC. /NEW/ (MLNT).
What therapeutic areas does MELINTA THERAPEUTICS, INC. /NEW/ focus on?
MELINTA THERAPEUTICS, INC. /NEW/ develops therapies across Infectious Disease, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.